ReviewFrontiers in pharmacology2026
Advances in the treatment of recurrent aphthous stomatitis: from synthetic and natural drugs to novel drug delivery systems.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrent aphthous stomatitis (RAS), the most common inflammatory disease of the oral mucosa, has a complex etiology and diverse pathogenesis. To date, no curative treatment exists. Recurrent oral ulcers severely impair patients' quality of life, making the development of highly effective and safe therapeutic strategies an urgent priority in current clinical research. Method: Literature references were sourced from publications retrieved via searches on GeenMedical, X-mol, CNKI, and PubMed using the search terms "recurrent aphthous stomatitis" OR "recurrent aphthous ulcer" OR "oral ulcer" AND "treatment" in English and Chinese. The focus was on two dimensions: drug types and delivery systems. Results: Synthetic drugs such as corticosteroids have clear efficacy, but their potential adverse reactions limit their long-term use. In contrast, natural medicinal components such as licorice and quercetin are gaining increasing attention because of their multitarget mechanisms of action, favorable safety profiles, and therapeutic effects. With respect to delivery systems, novel adhesion agents, microneedles, and nanomedicines currently in development have been evaluated. These advantages include prolonged retention time on ulcer surfaces, enhanced biosafety, improved therapeutic efficacy, and current limitations. Conclusion: Natural medicines have potential as novel therapeutic options with high efficacy and safety in clinical settings. By enhancing local drug retention and amplifying therapeutic effects, novel delivery systems open new avenues for RAS therapy. Integrating the therapeutic advantages of natural medicines with the precision and sustained-release characteristics of advanced delivery systems represents a key direction for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.